Two Treatments Show Benefits in Juvenile Myasthenia Gravis

(MedPage Today) — SAN FRANCISCO — Two studies demonstrated the benefits of treating juvenile myasthenia gravis (MG) with newer drugs.
Interim results from the phase II/III ADAPT Jr study showed that efgartigimod (Vyvgart), a drug approved…

Source link : https://www.medpagetoday.com/meetingcoverage/aanem/118275

Author :

Publish date : 2025-11-03 16:22:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Two Treatments Show Benefits in Juvenile Myasthenia Gravis

Amyloid-Binding Radiotracer Spurs Hope for Better ATTR-CM Diagnosis

Related Posts

Amyloid-Binding Radiotracer Spurs Hope for Better ATTR-CM Diagnosis

Self-Injected Med Shows Rapid, Sustained Benefit in gMG

Hospitalizations Tied to Supplement; A Package Full of Fingers; Harvard Explosion

FDA’s Top Drug Regulator Exits Amid Probe

Systemic Therapy for Sjögren Closer With Phase 3 Success

‘Energy Insecurity’ Tied to Anxiety, Depression Risk

Two Treatments Show Benefits in Juvenile Myasthenia Gravis

Amyloid-Binding Radiotracer Spurs Hope for Better ATTR-CM Diagnosis

Self-Injected Med Shows Rapid, Sustained Benefit in gMG

Hospitalizations Tied to Supplement; A Package Full of Fingers; Harvard Explosion

FDA’s Top Drug Regulator Exits Amid Probe

Systemic Therapy for Sjögren Closer With Phase 3 Success

‘Energy Insecurity’ Tied to Anxiety, Depression Risk

SpaceX’s Starlink and other satellites face growing threat from sun

Categories

Archives